Skip to main content

Advertisement

SpringerLink
Log in

Utilization and Costs of Antiepileptic Drugs in the Elderly

Still an Unsolved Issue

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The aging of the general population in industrialized countries has brought to public attention the increasing incidence of age- and aging-related clinical conditions. Management of multiple and chronic disorders has become a more important issue for healthcare authorities because of increasing requests for medical assistance, the greater numbers of drugs required and drug interactions reported, and the increase in treatment-related costs.

Epilepsy is a chronic clinical condition affecting both sexes and all ages with a worldwide distribution. The incidence of epilepsy, after childhood, increases with age and the cumulative risk of epilepsy by 80 years of age ranges from 1.3% to 4% in different study populations. Although the issues for people with epilepsy are similar for older and younger adults, the elderly may require more attention with regard to selection of antiepileptic drugs (AEDs) than younger patients. Elderly patients with newly diagnosed epilepsy are more likely to remain seizure-free on AED therapy than younger populations; however, the toxicity of AEDs in elderly patients is ill-defined because seizures may be difficult to recognize in this group and the symptoms and signs of toxicity can be attributed to other causes. Moreover, elderly people have chronic clinical conditions and are more likely to be taking medications that could possibly interfere with AEDs.

Some older AEDs such as phenobarbital and phenytoin should not be used in the elderly because of their pharmacokinetic and pharmacodynamic profiles. There is no evidence that new AEDs, despite their better tolerability profiles, are advantageous in terms of attaining freedom from seizures compared with older agents.

Older AEDs are much less expensive than the new compounds and, with some exceptions, appear to be more cost effective. New AEDs may be cost effective only in patients who are not able to tolerate or who are resistant to older compounds or when the use of an older drug is contraindicated. However, there are no cost-effectiveness studies in the elderly and further evidence is needed to confirm these assumptions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Ben-Menachem E. Strategy for utilization of new antiepileptic drugs. Curr Opin Neurol 2008; 21: 167–72

    Article  PubMed  CAS  Google Scholar 

  2. Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005; 9: 1–157: iii-iv

    PubMed  CAS  Google Scholar 

  3. Beghi E. Epilepsy. In: Feigin VL, Bennett DA, editors. Handbook of clinical neuroepidemiology. Hauppage (NY): Nova Science Publishers Inc., 2007: 123–65

    Google Scholar 

  4. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993; 34: 592–6

    Article  Google Scholar 

  5. Hauser WA, Annegers JF, Kurland LT. The incidence of epilepsy and unprovoked seizures in Rochester, Minnesota, 1935–1984. Epilepsia 1993; 34: 453–68

    Article  PubMed  CAS  Google Scholar 

  6. Forsgren L, Bucht G, Eriksson S, et al. Incidence and clinical characteristics of unprovoked seizures in adults: a prospective population-based study. Epilepsia 1996; 37: 224–9

    Article  PubMed  CAS  Google Scholar 

  7. Hussain SA, Haut SR, Lipton RB, et al. Incidence of epilepsy in a racially diverse, community-dwelling, elderly cohort: results from the Einstein aging study. Epilepsy Res 2006; 71: 195–205

    Article  PubMed  CAS  Google Scholar 

  8. Garrard J, Cloyd J, Gross C, et al. Factors associated with antiepileptic drug use among elderly nursing home residents. J Gerontol A Biol Sci Med Sci 2000; 55A: M384–92

    Article  Google Scholar 

  9. Hesdorffer DC, Hauser WA, Annegers JF, et al. Dementia and adult-onset unprovoked seizures. Neurology 1996; 46: 727–30

    Article  PubMed  CAS  Google Scholar 

  10. Hopkins A, Garman A, Clarke C. The first seizure in adult life: value of clinical features, electroencephalography, and computerised tomographic scanning in prediction of seizure recurrence. Lancet 1988; 1: 721–6

    Article  PubMed  CAS  Google Scholar 

  11. Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurology 2006; 13: 277–82

    Article  CAS  Google Scholar 

  12. Stephen LJ, Kelly K, Mohanraj R, et al. Pharmacological outcomes in older people with newly diagnosed epilepsy. Epilepsy Behav 2006; 8: 434–7

    Article  PubMed  Google Scholar 

  13. Leppik IE. Epilepsy in the elderly: scope of the problem. Int Rev Neurobiol 2007; 81: 1–14

    Article  PubMed  Google Scholar 

  14. Pilotto A, Franceschi M, Vitale D, et al. SOFIA Project Investigators. Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. Eur J Clin Pharmacol 2006; 62: 65–73

    Article  PubMed  Google Scholar 

  15. Nobili A, Tettamanti M, Frattura L, et al. Drug use by the elderly in Italy. Ann Pharmacother 1997; 31: 416–22

    PubMed  CAS  Google Scholar 

  16. Chen YF, Dewey ME, Avery AJ, et al. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Self-reported medication use for older people in England and Wales. J Clin Pharm Ther 2001; 26: 129–40

    Article  PubMed  CAS  Google Scholar 

  17. Veehof LJ, Stewart RE, Meyboom-de Jong B, et al. Adverse drug reactions and polypharmacy in the elderly in general practice. Eur J Clin Pharmacol 1999; 55: 533–6

    Article  PubMed  CAS  Google Scholar 

  18. Scottish Intercollegiate Guidelines Network. Diagnosis and management of epilepsy in adults. Edinburgh: Scottish Intercollegiate Guidelines Network, 2003

    Google Scholar 

  19. National Committee on Quality Assurance. Drugs to be avoided in elderly [online]. Available from URL: http://www.ncqa.org/Portals/0/Newsroom/2007/Drugs_Avoided_Elderly.pdf [Accessed 2009 Jan 14]

  20. Bergey GK. Initial treatment of epilepsy: special issues in treating the elderly. Neurology 2004; 63 (10 Suppl. 4): S40–8

    Article  PubMed  Google Scholar 

  21. Pugh MJV, Van Cott AC, Cramer JA, et al. Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000–2004. Neurology 2008; 70: 2171–8

    Article  PubMed  CAS  Google Scholar 

  22. Garrard J, Harms S, Hardie N, et al. Antiepileptic drug use in nursing home admissions. Ann Neurol 2003; 54: 75–85

    Article  PubMed  Google Scholar 

  23. Galimberti CA, Magri F, Magnani B, et al. Antiepileptic drug use and epileptic seizures in elderly nursing home residents: a survey in the province of Pavia, Northern Italy. Epilepsy Res 2006; 68: 1–8

    Article  PubMed  Google Scholar 

  24. Pugh MJ, Foreman PJ, Berlowitz DR. Prescribing antiepileptics for the elderly: differences between guideline recommendations and clinical practice. Drugs Aging 2006; 23: 861–75

    Article  PubMed  Google Scholar 

  25. Savica R, Beghi E, Mazzaglia G, et al. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000–2005. Eur J Neurol 2007; 14: 1317–21

    Article  PubMed  CAS  Google Scholar 

  26. Lott RS. Lamotrigine: treatment of epilepsy in the elderly. Consult Pharm 2003; 18: 979–92

    PubMed  Google Scholar 

  27. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005; 64: 1868–73

    Article  PubMed  CAS  Google Scholar 

  28. Saetre E, Perucca E, Isojarvi J, et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007; 48: 1292–302

    Article  PubMed  CAS  Google Scholar 

  29. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1000–15

    Article  PubMed  CAS  Google Scholar 

  30. Perucca E, Alexandre V, Tomson T. Old versus new antiepileptic drugs: the SANAD study. Lancet 2007; 370: 313

    Article  PubMed  Google Scholar 

  31. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094–120

    Article  PubMed  Google Scholar 

  32. Brodie MJ, Stephen LJ. Outcomes in elderly patients with newly diagnosed and treated epilepsy. Int Rev Neurobiol 2007; 81: 253–63

    Article  PubMed  Google Scholar 

  33. Beghi E, Garattini L, Ricci E, et al. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 2004; 45: 171–8

    Article  PubMed  Google Scholar 

  34. Hamer H, Spottke A, Aletsee C, et al. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006; 47: 2165–72

    Article  PubMed  Google Scholar 

  35. Swingler RJ, Davidson DL, Roberts RC, et al. The cost of epilepsy in patients attending a specialist epilepsy service. Seizure 1994; 3: 115–20

    Article  PubMed  CAS  Google Scholar 

  36. Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41: 342–51

    Article  PubMed  CAS  Google Scholar 

  37. Tetto A, Manzoni P, Millul A, et al. The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res 2002; 48: 207–16

    Article  PubMed  CAS  Google Scholar 

  38. De Zelicourt M, Buteau L, Fagnani F, et al. The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study). Active Coordination of the Longitudinal Observational Network in Epilepsy. Seizure 2000; 9: 88–95

    Article  PubMed  Google Scholar 

  39. Al-Zakwani I, Hanssens Y, Deleu D, et al. Annual direct medical cost and contributing factors to total cost of epilepsy in Oman. Seizure 2003; 12: 555–60

    Article  PubMed  Google Scholar 

  40. Jacoby A, Buck D, Baker G, et al. Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia 1998; 39: 776–86

    Article  PubMed  CAS  Google Scholar 

  41. Heaney DC, Shorvon SD, Sander JW, et al. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries. Epilepsia 2000; 41Suppl. 5: S37–44

    PubMed  Google Scholar 

  42. Heaney DC, Shorvon SD, Sander JW. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 1998; 39Suppl. 3: S19–25

    Article  PubMed  CAS  Google Scholar 

  43. Markowitz MA, Mauskopf JA, Halpern MT. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology 1998; 51: 1026–33

    Article  PubMed  CAS  Google Scholar 

  44. Biais L, Sheehy O, Saint-Hilaire JM, et al. Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy. Pharmacoeconomics 2005; 23: 493–503

    Article  Google Scholar 

  45. Hughes D, Cockerell OC. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure 1996; 5: 89–95

    PubMed  CAS  Google Scholar 

  46. Remak E, Hutton J, Price M, et al. A Markov model of treatment of newly diagnosed epilepsy in the UK. An initial assessment of cost-effectiveness of topiramate. Eur J Health Econ 2003; 4: 271–8

    Article  PubMed  CAS  Google Scholar 

  47. Van Hout BA, Gagnon DD, McNulty P, et al. The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data. Pharmacoeconomics 2003; 21: 315–26

    Article  PubMed  Google Scholar 

  48. Selai CE, Smith K, Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure 1999; 8: 8–13

    Article  PubMed  CAS  Google Scholar 

  49. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016–26

    Article  PubMed  CAS  Google Scholar 

  50. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 2008; 17: 181–6

    Article  PubMed  Google Scholar 

  51. Barti R. Antiepileptic drug-induced osteopathy: subtypes, pathogenesis, prevention, early diagnosis and treatment. Dtsch Med Wochenschr 2007; 132: 1475–9

    Article  Google Scholar 

  52. Pellock JM. Felbamate in epilepsy therapy: evaluating the risks. Drug Saf 1999; 21: 225–39

    Article  PubMed  CAS  Google Scholar 

  53. Wild JM, Ahn H, Baulac M, et al. Vigabatrin and epilepsy: lessons learned. Epilepsia 2007; 48: 1318–27

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Clinical Psychiatry, University of Milano Bicocca, Milan, Italy

    Massimiliano Beghi

  2. Department of Neuroscience, Psychiatry and Anesthesiology, University of Messina, Messina, Italy

    Rodolfo Savica

  3. Laboratory of Neurological Disorders, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

    Ettore Beghi

  4. Laboratory of Quality Assessment of Geriatric Therapies and Services, and Drug Information Services for the Elderly, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

    Alessandro Nobili

  5. Centro di Economia Sanitaria, Istituto di Ricerche Farmacologiche “Mario Negri”, Ranica (Bergamo), Italy

    Livio Garattini

Authors
  1. Massimiliano Beghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rodolfo Savica
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ettore Beghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandro Nobili
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Livio Garattini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimiliano Beghi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beghi, M., Savica, R., Beghi, E. et al. Utilization and Costs of Antiepileptic Drugs in the Elderly. Drugs Aging 26, 157–168 (2009). https://doi.org/10.2165/0002512-200926020-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0002512-200926020-00007

Keywords

Search

Navigation